ECKERT-&-ZIEGLER
14.4.2021 12:01:13 CEST | Business Wire | Press release
Eckert & Ziegler is proud to announce that it is expanding its production site in Berlin, Germany, with a new production facility for the contract manufacturing of radiopharmaceuticals. This new cGMP clean room suite with a total area of around 270 m² will be a 21 CFR 211 compliant, radiopharmaceutical manufacturing facility dedicated to late stage investigational and commercial stage radiopharmaceuticals and be operational from the first quarter of 2022. Together with a new U.S. based cGMP facility, Eckert & Ziegler will be able to provide radiopharmaceutical development services to companies looking for Europe, US and worldwide contract manufacturing.
“We have decided to make this investment to meet the growing global demand for radiopharmaceutical services in both imaging and therapy products. At the moment, a large number of radiopharmaceutical substances from international pharmaceutical companies are in advanced clinical trials, some of them for broad indications such as prostate cancer," explains Dr. Lutz Helmke, member of the Executive Board of Eckert & Ziegler AG and responsible for the Medical segment. “The new cGMP facility enables positioning as a European production and development partner for specialized pharmaceutical companies and innovative scientists. We offer them a wide range of radiopharmaceutical services under GLP and cGMP conditions."
The new cGMP suite, will enable Eckert & Ziegler to offer complete early development services, including process development and scale-up, CMC manufacturing, product release, stability programs and packaging. The company will be able to manufacture products on a clinical scale for phases I, II and III as well as for commercial use as a radiopharmaceutical contract manufacturer.
Eckert & Ziegler has a global presence as one of the leading partners of the radiopharmaceutical industry and has production and sales sites in 13 countries in Europe, North and South America and Asia.
In Wilmington (MA), USA, a production plant is currently being completed to manufacture Yttrium-90 solution for liver cancer treatment. In the future, the company will expand its European production capacity for Lutetium-177 labeled drugs to its U.S. site. Lutetium-177 is a coveted active ingredient in many new cancer therapy drugs. "Due to the large number of studies in which Lutetium-177 is being clinically tested worldwide, we expect an increasing demand for this isotope and related services in the coming years. Our production sites in Europe, Asia and North America ideally position Eckert & Ziegler to meet this demand," adds Dr. Lutz Helmke.
In Jintan (China), Eckert & Ziegler is investing up to EUR 50 million in the construction of a production facility for radiopharmaceuticals.
About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees, is one of the world's largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.
About Eckert & Ziegler Medical
The Medical segment of Eckert & Ziegler pools expertise from various areas to provide a comprehensive range of products and services for nuclear medicine, brachytherapy and more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005367/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vycellix to Provide Universal Cell Cancer Therapy Progress Reports at Upcoming Investor & Partnering Meetings4.6.2026 20:15:00 CEST | Press release
- June events include USA trade mission to Norway (Oslo), the EHA Annual Meeting (Stockholm) and BIO International Convention (San Diego) Vycellix, Inc., a biotechnology company developing next-generation allogeneic natural killer (NK) cell-based therapies designed to overcome the risk of immune rejection and redefine functional persistence with durability, today announced the Company will attend a series of upcoming investor and partnering meetings to share progress reports on the Company’s universal cell therapy platforms and product candidates targeting multiple myeloma, acute myeloid leukemia and urothelial cancers. Vycellix is attending: June 8-9: U.S. Department of Commerce Certified Trade Mission to Norway in Oslo June 11-14: European Hematology Association (EHA) 2026 Congress in Stockholm June 22-25: BIO International Convention in San Diego (Florida Pavilion, Booth# 1319) To request a meeting with Vycellix at any of these events, please contact Doug Calder at dcalder@vycellix.
Sodali & Co Appoints Fabio Bianconi as Head of Italy4.6.2026 19:15:00 CEST | Press release
Sodali & Co, the leading global capital markets-centric stakeholder advisory firm, today announced the appointment of Fabio Bianconi as Head of Italy, effective immediately. Fabio succeeds Andrea Di Segni, who will transition into a new role as Senior Relationship Advisor, where he will continue to support key client relationships and strategic initiatives across the firm. Fabio brings deep experience, strong client relationships, and a track record advising on complex mandates in the Italian market. He will lead Sodali’s continued growth and development in Italy, building on the firm’s established position in the region. Aneliya Crawford, Chief Partnerships Officer & Global Head of Shareholder Advisory of Sodali & Co, said: “Andrea has played a central role in the evolution of Sodali over more than two decades, helping establish the firm as a trusted global advisor in corporate governance and shareholder engagement. He built our Italian business into a leader in the market, as reflect
Belkin Expands Nintendo Switch 2 Accessories Ecosystem With New Charging Grip and Travel Bag4.6.2026 18:00:00 CEST | Press release
Following the January debut of Charging Case Pro, Belkin broadens its gaming portfolio with new ways to power, carry, and play Today, Belkin, a leading consumer electronics brand for 40 years, announced the expansion of its Nintendo Switch 2 accessories ecosystem with the launch of the GamingCharging Grip for Nintendo Switch 2 and Gaming Travel Bag for Nintendo Switch 2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604082278/en/ Belkin expands Nintendo Switch 2 accessories ecosystem with new Charging Grip and Travel Bag Following the January debut of the award-winning Charging Case Pro, the new accessories build on Belkin’s growing gaming portfolio, offering players more ways to power, protect and carry their gaming essentials wherever they play. After entering the gaming accessories category in June 2025, Belkin continues to expand its ecosystem with thoughtfully designed products that combine premium materials, practi
DEWA Opens Registration for WETEX 20264.6.2026 17:55:00 CEST | Press release
Dubai Electricity and Water Authority (DEWA) has opened registration for the 28th edition of the Water, Energy, Technology and Environment Exhibition (WETEX), which will take place from 20 to 22 October 2026 at the Dubai World Trade Centre. One of the leading specialised exhibitions of its kind in the world and the largest in the region, WETEX is convened by DEWA under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604642265/en/ DEWA opens registration for WETEX 2026 (Photo: AETOSWire) WETEX covers a wide range of sectors, including energy, water, environment, green development, digital transformation, artificial intelligence (AI), sustainability, decarbonisation, green mobility, green hydroge
LotusFlare’s DNO™ Cloud Powers the Launch of Pi in South Africa4.6.2026 17:49:00 CEST | Press release
LotusFlare, a leading provider of cloud-native, AI-driven digital commerce and monetization platforms for communications service providers (CSPs), today announced its partnership with MTN South Africa to power the launch of its new digital brand, Pi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604149542/en/ At the core of Pi is LotusFlare’s DNO™ Cloud—a fully digital, cloud-native BSS platform that enables delivering a seamless, app-first customer experience at scale. From onboarding to plan management, Pi customers can access 5G mobile, fixed wireless, and travel eSIM services within minutes—without contracts, credit checks, or call centres—through a single, intuitive interface. DNO™ Cloud underpins the entire Pi ecosystem, including front-end digital experiences, product catalog, order management, converged charging, billing, and eSIM orchestration. Deployed on public cloud infrastructure in compliance with South Afr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom